UTHR

503.86

0.58% -2.96

Dopo l'orario di chiusura: 503.86

United Therapeutics Corp (UTHR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché UTHR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$506.82

Aprire:

$502.44

Volume 24 ore:

439.15K

Relative Volume:

0.89

Capitalizzazione di mercato:

$21.61B

Reddito:

$3.17B

Utile/perdita netta:

$1.29B

Rapporto P/E:

18.60

EPS:

27.0947

Flusso di cassa netto:

$1.01B

1 W Prestazione:

+2.78%

1M Prestazione:

-4.87%

6M Prestazione:

-5.96%

1 anno Prestazione:

+27.08%

Intervallo 1D:

$497.91

$509.79

Intervallo di 1 settimana:

$479.71

$509.79

Portata 52W:

$395.00

$609.35

United Therapeutics Corp Stock (UTHR) Company Profile

Nome

United Therapeutics Corp

Settore

Healthcare (1069)

Industria

Drug Manufacturers - Specialty & Generic (87)

Telefono

(301) 608-9292

Indirizzo

1000 SPRING ST, SILVER SPRING, MD

Dipendente

1,400

Cinguettio

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

UTHR's Discussions on Twitter

Compare UTHR vs TAK, TEVA, HLN, ZTS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
UTHR United Therapeutics Corp	503.86	21.74B	3.17B	1.29B	1.01B	27.09
TAK Takeda Pharmaceutical Co Adr	18.11	58.15B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.35	42.94B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.22	40.59B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.86	30.29B	9.51B	2.64B	2.14B	6.0361

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-10	Iniziato	Raymond James	Outperform
2025-10-20	Iniziato	Wells Fargo	Underweight
2025-09-26	Iniziato	RBC Capital Mkts	Outperform
2025-06-02	Iniziato	Cantor Fitzgerald	Overweight
2025-04-25	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-04-21	Aggiornamento	BofA Securities	Underperform → Neutral
2024-07-11	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-02-12	Aggiornamento	Goldman	Sell → Neutral
2024-02-05	Iniziato	Leerink Partners	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2022-12-06	Iniziato	UBS	Buy
2022-12-05	Iniziato	Goldman	Sell
2022-10-11	Iniziato	Morgan Stanley	Overweight
2022-09-20	Reiterato	BofA Securities	Underperform
2022-09-19	Ripresa	Wedbush	Outperform
2022-02-11	Iniziato	BTIG Research	Neutral
2021-07-14	Aggiornamento	Argus	Hold → Buy
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-02-01	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-06-25	Reiterato	H.C. Wainwright	Neutral
2020-03-10	Aggiornamento	Jefferies	Hold → Buy
2020-02-27	Aggiornamento	Cowen	Market Perform → Outperform
2020-01-31	Aggiornamento	JP Morgan	Neutral → Overweight
2019-12-03	Iniziato	BofA/Merrill	Underperform
2019-08-01	Aggiornamento	Jefferies	Underperform → Hold
2019-08-01	Aggiornamento	Ladenburg Thalmann	Neutral → Buy
2019-07-01	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-05-17	Aggiornamento	UBS	Sell → Neutral
2019-05-09	Aggiornamento	Credit Suisse	Underperform → Neutral
2018-10-12	Aggiornamento	Standpoint Research	Hold → Buy
2018-08-08	Downgrade	Credit Suisse	Neutral → Underperform
2018-04-03	Aggiornamento	Credit Suisse	Underperform → Neutral
2018-02-22	Reiterato	Barclays	Underweight
2018-01-18	Ripresa	Credit Suisse	Underperform
2017-12-27	Reiterato	Wedbush	Outperform
2017-04-27	Reiterato	Wedbush	Outperform
2017-03-30	Iniziato	UBS	Sell
2017-03-16	Iniziato	Credit Suisse	Underperform

Mostra tutto

United Therapeutics Corp Borsa (UTHR) Ultime notizie

04:31 AM

United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan

04:31 AM

05:47 AM

United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia

05:47 AM

Sep 09, 2026

United Therapeutics at Cantor healthcare conference: fibrosis push widens By Investing.com - Investing.com Australia

Sep 09, 2026

United Therapeutics CEO Martine Rothblatt sells $4.7m in stock - Investing.com

Sep 09, 2026

United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares in preset plan - Stock Titan

Sep 09, 2026

Sep 08, 2026

United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart

Sep 08, 2026

United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView

Sep 08, 2026

United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan

Sep 08, 2026

United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan

Sep 08, 2026

United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus

Sep 08, 2026

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com

Sep 08, 2026

Sep 07, 2026

United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews

Sep 07, 2026

Sep 04, 2026

United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan

Sep 04, 2026

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits

Sep 04, 2026

United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Sep 04, 2026

Sep 03, 2026

Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M - UnionLeader.com

Sep 03, 2026

United Therapeutics EVP Paul A. Mahon Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com

Sep 03, 2026

United Therapeutics (UTHR) counsel sells 8,300 shares under preset plan - Stock Titan

Sep 03, 2026

United Therapeutics (UTHR) CEO offloads 9,500 shares in planned trade - Stock Titan

Sep 03, 2026

United Therapeutics (NASDAQ:UTHR) Offers Growth At A Fair Price - Kalkine Media

Sep 03, 2026

United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model - ChartMill

Sep 03, 2026

Sep 02, 2026

Merrimack’s Anheuser-Busch property sold for $47m - The Cabinet Press

Sep 02, 2026